Geodon (ziprasidone), a new atypical antipsychotic for schizophrenia

March 2001

Pfizer will soon market Geodon (ziprasidone), a new atypical antipsychotic for schizophrenia.

Geodon will be widely used because it appears to cause less weight gain than other atypicals...Zyprexa, Risperdal, or Seroquel.

Weight gain causes some patients to discontinue therapy...and it increases the risk of developing diabetes and heart disease.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote